ProShare Advisors’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $539K | Sell |
2,021
-733
| -27% | -$171K | ﹤0.01% | 1039 |
|
|
2026
Q1 | $630K | Buy |
2,754
+42
| +2% | +$9.41K | ﹤0.01% | 952 |
|
|
2025
Q4 | $578K | Buy |
2,712
+544
| +25% | +$112K | ﹤0.01% | 1057 |
|
|
2025
Q3 | $431K | Sell |
2,168
-97
| -4% | -$18.1K | ﹤0.01% | 1192 |
|
|
2025
Q2 | $391K | Sell |
2,265
-459
| -17% | -$74.8K | ﹤0.01% | 1264 |
|
|
2025
Q1 | $425K | Sell |
2,724
-133
| -5% | -$19K | ﹤0.01% | 1187 |
|
|
2024
Q4 | $393K | Sell |
2,857
-567
| -17% | -$74.5K | ﹤0.01% | 1433 |
|
|
2024
Q3 | $511K | Sell |
3,424
-152
| -4% | -$20.5K | ﹤0.01% | 1124 |
|
|
2024
Q2 | $488K | Sell |
3,576
-449
| -11% | -$61.1K | ﹤0.01% | 992 |
|
|
2024
Q1 | $608K | Buy |
4,025
+361
| +10% | +$51.5K | ﹤0.01% | 976 |
|
|
2023
Q4 | $461K | Sell |
3,664
-67
| -2% | -$6.68K | ﹤0.01% | 1088 |
|
|
2023
Q3 | $349K | Buy |
3,731
+39
| +1% | +$3.65K | ﹤0.01% | 1126 |
|
|
2023
Q2 | $330K | Sell |
3,692
-256
| -6% | -$22.3K | ﹤0.01% | 1210 |
|
|
2023
Q1 | $423K | Sell |
3,948
-671
| -15% | -$76.8K | ﹤0.01% | 991 |
|
|
2022
Q4 | $564K | Sell |
4,619
-48
| -1% | -$5.57K | ﹤0.01% | 913 |
|
|
2022
Q3 | $482K | Buy |
4,667
+347
| +8% | +$32.9K | ﹤0.01% | 912 |
|
|
2022
Q2 | $402K | Sell |
4,320
-1,418
| -25% | -$134K | ﹤0.01% | 1036 |
|
|
2022
Q1 | $673K | Sell |
5,738
-2,051
| -26% | -$238K | ﹤0.01% | 1107 |
|
|
2021
Q4 | $1.05M | Sell |
7,789
-3,389
| -30% | -$504K | ﹤0.01% | 993 |
|
|
2021
Q3 | $1.78M | Buy |
11,178
+1,790
| +19% | +$245K | 0.01% | 746 |
|
|
2021
Q2 | $1.24M | Buy |
9,388
+2,169
| +30% | +$289K | ﹤0.01% | 916 |
|
|
2021
Q1 | $930K | Sell |
7,219
-775
| -10% | -$118K | ﹤0.01% | 1035 |
|
|
2020
Q4 | $1.33M | Buy |
7,994
+464
| +6% | +$76.7K | 0.01% | 761 |
|
|
2020
Q3 | $1.16M | Buy |
7,530
+154
| +2% | +$22.1K | 0.01% | 683 |
|
|
2020
Q2 | $1.09M | Buy |
7,376
+1,059
| +17% | +$145K | 0.01% | 680 |
|
|
2020
Q1 | $711K | Sell |
6,317
-3,595
| -36% | -$467K | 0.01% | 663 |
|
|
2019
Q4 | $1.38M | Sell |
9,912
-2,453
| -20% | -$273K | 0.01% | 705 |
|
|
2019
Q3 | $1.19M | Sell |
12,365
-787
| -6% | -$87.8K | 0.01% | 706 |
|
|
2019
Q2 | $1.51M | Sell |
13,152
-532
| -4% | -$63.7K | 0.01% | 646 |
|
|
2019
Q1 | $1.61M | Buy |
13,684
+236
| +2% | +$20.7K | 0.01% | 647 |
|
|
2018
Q4 | $843K | Sell |
13,448
-2,656
| -16% | -$167K | 0.01% | 758 |
|
|
2018
Q3 | $1.14M | Buy |
16,104
+264
| +2% | +$18.2K | 0.01% | 775 |
|
|
2018
Q2 | $1.05M | Buy |
15,840
+750
| +5% | +$49.3K | 0.01% | 805 |
|
|
2018
Q1 | $987K | Sell |
15,090
-2,160
| -13% | -$121K | 0.01% | 824 |
|
|
2017
Q4 | $691K | Buy |
+17,250
| New | +$627K | ﹤0.01% | 986 |
|
Other funds holding ASND
RCM
ACA
JT
ProShare Advisors's ASND Position: Q2 2026 in Review
ProShare Advisors reduced its Ascendis Pharma A/S (ASND) stake by 27% in Q2 2026, selling an estimated $171K and leaving 2,021 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #1039.
ProShare Advisors first reported a position in ASND in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.78M in Q3 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- ProShare Advisors held 2,021 shares of Ascendis Pharma A/S worth $539K as of Q2 2026.
- ProShare Advisors sold 733 Ascendis Pharma A/S shares in Q2 2026, an estimated $171K.
- Ascendis Pharma A/S made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1039 holding.
- ProShare Advisors first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 35 quarters since.
- ProShare Advisors's Ascendis Pharma A/S position peaked at $1.78M in Q3 2021.
- 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.